A History of Impact
From the beginning, our goal has been to take on tough health challenges. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community, and uncompromising integrity at the heart of everything we do. But we haven’t come this far to only come this far.
Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact that lasts.
AbbVie celebrates a decade of impact
Over the ten years since launching as an independent company, we’ve solved tough challenges so we can raise the standard of treatment for all, investing over $50 billion to discover and develop new medicines. As we look toward the future, we will continue to innovate and grow, creating medicines and solutions that put impact first – for patients, communities and our world.
Commitment to Improve our Local Communities North Chicago’s New Public Grade School Opens, Funded by a Donation from AbbVie
AbbVie and the North Chicago Community Unit School District 187 opened the new Neal Math and Science Academy, the district’s only middle school, built with a $40 million donation from AbbVie. Constructed with a focus on STEM learning, it was designed in collaboration with the school district, AbbVie, students and the community. The donation is one example of AbbVie’s longstanding commitment to improve student success and support children, families and the community.
AbbVie volunteers return to serving global communities through Week of Possibilities
After a two-year pause due to the pandemic, approximately 15,000 employees in more than 50 countries returned to serve in-person in our seventh annual Week of Possibilities. Over the course of a week, volunteers worked with trusted community partners to complete hands-on projects aimed at strengthening local communities, expanding educational programs and making a positive environmental impact.
Aesthetic Product celebrates 20 years since first U.S. FDA approval
The iconic brand was the first product of its kind to receive U.S Food and Drug Administration food approval in 2002 for aesthetic use.
AbbVie opens new facility in the Bay Area
In the birthplace of biotech, we continue our investment in innovation. The new 480,000 square-foot facility puts all our cross-functional experts in the Bay Area under one roof, opening up more opportunities for collaboration and innovation in oncology research and development.
AbbVie ranked #4 on FORTUNE’s list of World's Best Workplaces™ 2021
We are proud to have been ranked #4 – a jump of 11 spots from 2020 – on FORTUNE’s 2021 World’s Best Workplaces list following the magazine’s massive, data-led annual analysis of corporate culture at more than 10,000 companies around the globe. This marks AbbVie’s third consecutive ranking on this list and validates the incredible collaboration between our 48,000+ global employees and their commitment to making a remarkable impact for patients each day.
Our migraine treatment received U.S. FDA approval
U.S. FDA approval for the preventative treatment of episodic migraine in adults. This achievement renders AbbVie the only pharmaceutical company to offer three treatments across the full migraine spectrum, and we are proud to offer another treatment possibility to patients living with this debilitating disease.
Allergan Aesthetics launches new brand identity
Allergan Aesthetics, an AbbVie company, launched its new global brand identity focused on empowering confidence. The new brand also promotes diversity by recognizing people from different genders, ethnicities and skin tones to show dedication to developing aesthetic medicine for everyone.
Our commitment to equality
AbbVie is committed to making a positive impact in the fight for racial justice. To address the ongoing issues in our criminal justice system, we’ve donated $5 million to the NAACP Legal Defense and Education Fund and the Equal Justice Initiative. Over the next five years, we are partnering with nonprofits in our communities to donate an additional $50 million.
Allergan joins AbbVie
AbbVie’s acquisition of Allergan accelerated our efforts in delivering groundbreaking medicines around the world. We’re investing more into research and development, expanding into new therapeutic areas and transforming the opportunities ahead.
Our response to the COVID-19 pandemic
AbbVie is committed to addressing the COVID-19 public health crisis. We’ve partnered with health authorities and institutions to accelerate R&D into treatment and prevention. Additionally, AbbVie donated $35 million to underserved communities and healthcare systems.
From collaborating in clinical research to providing equipment and supplies, we’ll continue to keep the health and safety of communities and our employees at the forefront of our efforts.
Our rheumatoid arthritis treatment received U.S. FDA approval
Our rheumatoid arthritis treatment was granted U.S. FDA for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate, marking our second U.S. FDA approval of a targeted immunomodulator (TIM) therapy in 2019. This milestone continues our long-standing commitment to advancing the treatments available for people living with immune-mediated conditions.
AbbVie honored on CR Magazine’s annual 100 Best Corporate Citizens List
Corporate responsibility is a critical part of who we are as a company, which is why we were delighted to be ranked 17th on CR Magazine’s annual 100 Best Corporate Citizens List. This influential list recognizes outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies.
Our plaque psoriasis treatment received global regulatory approvals
AbbVie received both U.S. FDA and European Commission approvals for our treatment of severe plaque psoriasis, a chronic condition affecting 125 million people worldwide.
AbbVie donated $40 million to rebuild North Chicago middle school
AbbVie donated $40 million to fund the rebuilding of the district’s only middle school, Neal Math and Science Academy, to help improve student success and graduation rates, reduce dropout rates and increase college and career readiness. The middle school capped off our $350 million nonprofit charitable contribution pledge in 2018 and built on our longstanding commitment to investing in North Chicago.
U.S. FDA accelerated approval for newly-diagnosed acute myeloid leukemia (AML) patients
AbbVie was granted accelerated approval for a treatment for newly-diagnosed AML in adults 75 years or older, or who have comorbidities that preclude intensive induction chemotherapy. AML is one of the most aggressive blood cancers, and this new approval marked a significant milestone for patients diagnosed with this disease.
AbbVie donated $100 million to Ronald McDonald House Charities
This contribution, the largest single donation in both AbbVie and Ronald McDonald House Charities history, provided essential support such as housing, meals and education for hospitalized children and their families across America.
Our treatment for endometriosis was approved by the U.S. FDA
We received the first U.S. FDA approval in over a decade for an oral treatment of the moderate-to-severe pain associated with endometriosis, one of the most common gynecologic disorders in the U.S.
AbbVie recognized as a FORTUNE 100 Best Company to Work For
In 2018, we were proud to be featured in the FORTUNE 100 Best Companies to Work For list for the first time. At AbbVie, culture has always been a strategic priority, and our employees are unified by a commitment to make a remarkable impact on patients’ lives.
The U.S. FDA approved treatment for chronic graft-versus-host-disease (cGVHD)
Nearly half of transplant patients develop chronic graft-versus-host-disease, or cGVHD, in which the donor's immune cells damage the patient's normal organs and their quality of life.
MAVIRET™ / MAVYRET™ (glecaprevir/pibrentasvir) was approved in U.S., European Union and Japan
This approval reflects our commitment to advance vision care and expands our leading portfolio of treatments for eye care providers and their patients.
AbbVie topped Reputation Institute List for global pharma companies
Reputation Institute Global Pharma RepTrak® named AbbVie the 2017 Most Reputable Pharmaceutical Company, based on more than 16,500 reputation ratings collected among the general public in Brazil, Canada, France, Italy, Germany, Spain, United Kingdom and the United States.
AbbVie led biotech industry in Dow Jones Sustainability World Index
For the third year in a row, AbbVie placed highly on the Dow Jones Sustainability World Index, which measures performance of the world’s largest companies based on long-term economic, environmental, and social criteria and business practices that create long-term shareholder value. In 2016, we had the highest industry score on 12 of 22 criteria.
Our treatment for uveitis was approved by the U.S. Food and Drug Administration
We received U.S. FDA approval for our biologic treatment for non-infectious uveitis, an immune-mediated disease that can flare and impair vision.
We earned new approvals for IMBRUVICA® (ibrutinib) and VENCLEXTA™ / VENCLYXTO™ (Venetoclax)
By earning these approvals in the United States and European Union, we furthered our commitment to tackling the world's toughest diseases.
IMBRUVICA® (ibrutinib) awarded Prix Galien 2015 Best Pharmaceutical Agent
Considered to be the biomedical industry's highest accolade, the Prix Galien Award recognizes outstanding achievement in the development of new therapies. Worldwide, the Prix Galien Award is generally regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
AbbVie made Working Mother of the Year list for 3rd year in a row
Working Mother magazine recognized AbbVie among its “Working Mother 100 Best Companies” for the third consecutive year. This recognition is given for outstanding leadership in creating progressive programs, advancement of women, flexibility, childcare and paid parental leave for employees like Sandra.
AbbVie medicines impact over 30 million patients around the world
With a new indication approval in the United States, we had collectively served over 30 million patients worldwide with our medicines.
Inaugural Week of Possibilities begins
What started in 2014 as a primarily headquarters-based week of service involving a thousand employees, has since become a global AbbVie tradition with more than 7,000 employees in nearly 60 countries. See the impact of our Week of Possibilities around the world.
“The AbbVie Way” became a unified culture
Our new company needed its own culture, and we quickly got to work implementing changes that would drive performance and success through our business, our culture and our remarkable impact. Find out how we built “The AbbVie Way,” and what it means to truly live it.
AbbVie ranked 4th on Science magazine's list of top science employers
After less than a year of existence, AbbVie ranked 4th on Science magazine's annual list of Top Science Employers, as surveyed by more than 3,000 respondents.
We earned our first breakthrough therapy designation from the U.S. Food and Drug Administration
With 71 million people worldwide infected with hepatitis C (HCV), our ongoing commitment to those living with the virus means understanding their journey. That's why we were thrilled when the U.S. FDA gave us this designation, intended to expedite the development and review of drugs for serious or life-threatening conditions, for our investigational HCV regimen.
The first AbbVie-branded product was released into the world
The first batch of AbbVie-branded product rolled off the production line. Within 24 hours, approximately 23,000 finished cartons had been made for patients in the United States.
AbbVie Celebrated Launch as New Biopharmaceutical Company
On January 2, 2013, we rang the opening bell on the New York Stock Exchange to mark our first official day as a new biopharmaceutical company. With an initial stock price of $34.40 per share, we hit the ground running, solidifying our patient-centered mission and began creating our culture of agility and accountability.